.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Queensland Health
Boehringer Ingelheim
US Department of Justice
Citi
Accenture
AstraZeneca
UBS
Argus Health
Moodys

Generated: December 17, 2017

DrugPatentWatch Database Preview

Dalfampridine - Generic Drug Details

« Back to Dashboard

What are the generic sources for dalfampridine and what is the scope of dalfampridine freedom to operate?

Dalfampridine
is the generic ingredient in two branded drugs marketed by Acorda, Actavis Labs Fl Inc, and Aurobindo Pharma Ltd, and is included in three NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Dalfampridine has fifty-five patent family members in twenty-three countries and twenty-two supplementary protection certificates in nine countries.

There are nine drug master file entries for dalfampridine. One supplier is listed for this compound. There are five tentative approvals for this compound.

Pharmacology for dalfampridine

Tentative approvals for DALFAMPRIDINE

Applicant Application No. Strength Dosage Form
u► Subscribe10MGTABLET, EXTENDED RELEASE;ORAL
u► Subscribe10MGTABLET, EXTENDED RELEASE;ORAL
u► Subscribe0.0TABLET;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe
Actavis Labs Fl IncDALFAMPRIDINEdalfampridineTABLET, EXTENDED RELEASE;ORAL206836-001Jan 23, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe
Aurobindo Pharma LtdDALFAMPRIDINEdalfampridineTABLET, EXTENDED RELEASE;ORAL206811-001Jan 23, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: dalfampridine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: dalfampridine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,370,879 Formulations and their use in the treatment of neurological diseases► Subscribe
5,580,580 Formulations and their use in the treatment of neurological diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: dalfampridine

Country Document Number Estimated Expiration
Japan5736100► Subscribe
MexicoPA06011648► Subscribe
CroatiaP20130424► Subscribe
Portugal2377536► Subscribe
Japan2012188427► Subscribe
Japan2012188427► Subscribe
Spain2367707► Subscribe
Hong Kong1162971► Subscribe
European Patent Office2422782► Subscribe
European Patent Office1732548► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: DALFAMPRIDINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0033France► SubscribePRODUCT NAME: FAMPRIDINE OU L'UN DE SES DERIVES; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110725
0612Netherlands► SubscribePRODUCT NAME: 4-AMINOPYRIDINE, DAN WEL EEN DERIVAAT DAARVAN, IN HET BIJZONDER EEN ZOUT, SOLVAAT OF PRODRUG; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720
2012001Lithuania► SubscribePRODUCT NAME: FAMPRIDINUM; REGISTRATION NO/DATE: EU/1/11/699/001 - EU/1/11/699/002 20110720
0120002 00051Estonia► SubscribePRODUCT NAME: FAMPYRA - FAMPRIDINE;REG NO/DATE: C(2011)5390 FINAL 20.07.2011
90033-9Sweden► SubscribePRODUCT NAME: 4-AMINOPYRIDIN ELLER ETT SALT DAERAV; REG. NO/DATE: EU/1/11/699/001 20110720
2013015,C2377536Lithuania► SubscribePRODUCT NAME: FAMPRIDINUM; REGISTRATION NO/DATE: EU/1/11/699/001 - EU/1/11/699/002 20110720
2011100058Germany► SubscribePRODUCT NAME: FAMPYRA - ZUSAMMENSETZUNG UMFASSEND FAMPRIDIN SOWIE SALZE ODER ESTER DAVON; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720
2011 00031Denmark► SubscribePRODUCT NAME: 4-AMINOPYRIDIN ELLER ET SALT DERAF, HERUNDER FAMPRIDIN; REG. NO/DATE: EU/1/11/699/001-002 20110720
C0049France► SubscribePRODUCT NAME: FAMPRIDINE OU L'UN DE SES DERIVES; REGISTRATION NO/DATE: EU/1/11/699/001 20110720
894Luxembourg► Subscribe91894, EXPIRES: 20161101
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Julphar
Citi
Cerilliant
McKinsey
McKesson
Cipla
Fuji
Baxter
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot